Evidence map›Paper›PMID 41310387›Full record

SynthesisScientific reports2025

Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis.

Jiawen Qian, Xiujie Lv, Yuxin Hu, Yuxin Zhang, Rong Zhou, Chenyi Yuan, Zhehao Huang, Xiangfu Gao, Yuan Gao, Yuancheng Gao

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiawen QianThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Xiujie LvThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Yuxin HuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 101121, China.
Yuxin ZhangThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310021, China.
Rong ZhouChangxing County Hospital of Traditional Chinese Medicine, Huzhou, 313100, China.
Chenyi YuanThe First Affiliated Hospital of Ningbo University, Ningbo, 315000, China.
Zhehao HuangThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Xiangfu GaoThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Yuan GaoCapital Medical University, Beijing, 100069, China.
Yuancheng GaoThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China. 20233178@zcmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cell-targeted therapies play an important role in systemic lupus erythematosus (SLE). Belimumab targets B lymphocyte stimulator (BLyS), whereas telitacicept inhibits both BLyS and APRIL. Although both drugs have demonstrated clinical efficacy in SLE, comparative benefits and risks of telitacicept versus belimumab remain unclear. We performed a systematic review and meta-analysis using indirect comparisons to compare their efficacy and safety. We searched 6 database for randomized controlled trials (RCTs) published up to November 1, 2025, without language restriction. Trials evaluating belimumab or telitacicept in adult SLE patients were included. Primary outcomes included SLE Responder Index 4 (SRI4), SRI7 response rates and decreasing SLEDAI score. Secondary outcomes included prednisone dose reduction, anti-dsDNA change, adverse events (AEs) and serious AEs. Data extraction and risk-of-bias assessment were performed independently by two reviewers. Analysis used RR with 95% CI, and heterogeneity was assessed by I

Indexed as

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsLupus Erythematosus, SystemicRecombinant Fusion ProteinsAdultB-Cell Activating FactorHumansPrednisoneRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedB-Cell Activating FactorbelimumabImmunosuppressive AgentsPrednisoneRecombinant Fusion Proteinstelitacicept

Identifiers

PMID41310387
PMCPMC12748641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.